333 related articles for article (PubMed ID: 22150431)
21. p110α and p110β isoforms of PI3K are involved in protection against H
Singh P; Bano N; Hossain MM; Basit R; Dar MJ
Breast Cancer; 2019 May; 26(3):378-385. PubMed ID: 30499025
[TBL] [Abstract][Full Text] [Related]
22. High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation.
Tzenaki N; Andreou M; Stratigi K; Vergetaki A; Makrigiannakis A; Vanhaesebroeck B; Papakonstanti EA
FASEB J; 2012 Jun; 26(6):2498-508. PubMed ID: 22391131
[TBL] [Abstract][Full Text] [Related]
23. Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases.
Rodgers SJ; Ferguson DT; Mitchell CA; Ooms LM
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28082369
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic signaling of class I PI3K isoforms.
Denley A; Kang S; Karst U; Vogt PK
Oncogene; 2008 Apr; 27(18):2561-74. PubMed ID: 17998941
[TBL] [Abstract][Full Text] [Related]
25. P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.
Iyengar S; Clear A; Bödör C; Maharaj L; Lee A; Calaminici M; Matthews J; Iqbal S; Auer R; Gribben J; Joel S
Blood; 2013 Mar; 121(12):2274-84. PubMed ID: 23341541
[TBL] [Abstract][Full Text] [Related]
26. Should individual PI3 kinase isoforms be targeted in cancer?
Jia S; Roberts TM; Zhao JJ
Curr Opin Cell Biol; 2009 Apr; 21(2):199-208. PubMed ID: 19200708
[TBL] [Abstract][Full Text] [Related]
27. Phosphoinositide 3-kinases p110α and p110β have differential roles in insulin-like growth factor-1-mediated Akt phosphorylation and platelet priming.
Blair TA; Moore SF; Williams CM; Poole AW; Vanhaesebroeck B; Hers I
Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1681-8. PubMed ID: 24903091
[TBL] [Abstract][Full Text] [Related]
28. Both p110alpha and p110beta isoforms of phosphatidylinositol 3-OH-kinase are required for insulin signalling in the hypothalamus.
Tups A; Anderson GM; Rizwan M; Augustine RA; Chaussade C; Shepherd PR; Grattan DR
J Neuroendocrinol; 2010 Jun; 22(6):534-42. PubMed ID: 20236230
[TBL] [Abstract][Full Text] [Related]
29. Specific role of phosphoinositide 3-kinase p110alpha in the regulation of phagocytosis and pinocytosis in macrophages.
Tamura N; Hazeki K; Okazaki N; Kametani Y; Murakami H; Takaba Y; Ishikawa Y; Nigorikawa K; Hazeki O
Biochem J; 2009 Sep; 423(1):99-108. PubMed ID: 19604150
[TBL] [Abstract][Full Text] [Related]
30. Phosphoinositide 3-kinases p110alpha and p110beta regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase.
Marqués M; Kumar A; Cortés I; Gonzalez-García A; Hernández C; Moreno-Ortiz MC; Carrera AC
Mol Cell Biol; 2008 Apr; 28(8):2803-14. PubMed ID: 18285463
[TBL] [Abstract][Full Text] [Related]
31. Dominant Role of PI3K p110α over p110β in Insulin and β-Adrenergic Receptor Signalling.
Zhang B; Luk C; Valadares J; Aronis C; Foukas LC
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884613
[TBL] [Abstract][Full Text] [Related]
32. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling.
Chaussade C; Rewcastle GW; Kendall JD; Denny WA; Cho K; Grønning LM; Chong ML; Anagnostou SH; Jackson SP; Daniele N; Shepherd PR
Biochem J; 2007 Jun; 404(3):449-58. PubMed ID: 17362206
[TBL] [Abstract][Full Text] [Related]
33. Dominant role of the p110beta isoform of PI3K over p110alpha in energy homeostasis regulation by POMC and AgRP neurons.
Al-Qassab H; Smith MA; Irvine EE; Guillermet-Guibert J; Claret M; Choudhury AI; Selman C; Piipari K; Clements M; Lingard S; Chandarana K; Bell JD; Barsh GS; Smith AJ; Batterham RL; Ashford ML; Vanhaesebroeck B; Withers DJ
Cell Metab; 2009 Nov; 10(5):343-54. PubMed ID: 19883613
[TBL] [Abstract][Full Text] [Related]
34. PTEN and Other PtdIns(3,4,5)P
Csolle MP; Ooms LM; Papa A; Mitchell CA
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33276499
[TBL] [Abstract][Full Text] [Related]
35. CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells.
Zhang J; Gao X; Schmit F; Adelmant G; Eck MJ; Marto JA; Zhao JJ; Roberts TM
Cell Rep; 2017 Jul; 20(3):549-557. PubMed ID: 28723560
[TBL] [Abstract][Full Text] [Related]
36. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.
Ni J; Liu Q; Xie S; Carlson C; Von T; Vogel K; Riddle S; Benes C; Eck M; Roberts T; Gray N; Zhao J
Cancer Discov; 2012 May; 2(5):425-33. PubMed ID: 22588880
[TBL] [Abstract][Full Text] [Related]
37. PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.
Miller KA; Degan S; Wang Y; Cohen J; Ku SY; Goodrich DW; Gelman IH
Oncogene; 2024 Jan; 43(1):22-34. PubMed ID: 37875657
[TBL] [Abstract][Full Text] [Related]
38. The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome.
Wang Q; Weisberg E; Zhao JJ
Cell Cycle; 2013 Dec; 12(23):3589-93. PubMed ID: 24131925
[TBL] [Abstract][Full Text] [Related]
39. Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers.
Zhu Q; Youn H; Tang J; Tawfik O; Dennis K; Terranova PF; Du J; Raynal P; Thrasher JB; Li B
Oncogene; 2008 Jul; 27(33):4569-79. PubMed ID: 18372911
[TBL] [Abstract][Full Text] [Related]
40. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
